
Weight & GLP-1
Reads the receptors that semaglutide and tirzepatide act on, and the two best-studied appetite genes, FTO and MC4R, and sets each reading against what the trials found. In 27,885 people on GLP-1 medicines, one receptor version went with about 0.76 kg more weight lost per copy, against a trial average of 15 to 21 % of body weight.
No gene test yet tells who will respond. Nothing in the report is a reason to start or stop a medicine; that stays with you and your prescriber.



